Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: Interim phase II results from an ongoing, randomized study Meeting Abstract
| Authors: | DiNardo, C. D.; Schuh, A. C.; Stein, E. M.; Montesinos Fernandez, P.; Wei, A.; De Botton, S.; Zeidan, A. M.; Fathi, A. T.; Quek, L.; Kantarjian, H. M.; Frattini, M. G.; Lersch, F.; Gong, J.; Franovic, A.; MacBeth, K.; Vyas, P.; Döhner, H. |
| Abstract Title: | Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: Interim phase II results from an ongoing, randomized study |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Start Page: | 643 |
| Language: | English |
| ACCESSION: | WOS:000518218500421 |
| DOI: | 10.1182/blood-2019-130362 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 613 -- Source: Wos |
